Hadly Clark is an associate director on the FasterCures team at Milken Institute Health. She is an experienced health care professional focused on the intersection of health and technology and leads oncology-focused initiatives exploring innovative screening technologies and anti-cancer treatments.
The United States—as of June 2020—has more reported cases of COVID-19 than any other country in the world, despite having many of the same resources as other countries that curbed the pandemic more successfully. COVID-19 has highlighted the cracks in the United States’ health-care system; specifically, it has exposed inefficiencies in the mechanisms, like data collection, through which care informs medical research.
Reflecting a widespread desire to collaborate in the fight against the virus, big tech and public-private partnerships have undertaken many initiatives to help “flatten the curve” through patient data collection. However, efforts to report data remain uncoordinated, exposing a lack of data interoperability, an inability to aggregate data from disparate sources, difficulties with analyzing data in real time, and a crisis of consumer trust in big tech.
This paper explores these challenges in relation to medical research and discusses how the COVID-19 pandemic has highlighted their importance. It also provides recommendations across several key thematic areas, including promoting the interoperability and integration of data, ensuring data privacy and protections, and advancing remote patient monitoring and telehealth.
The rapid advancement of the health technology landscape relies heavily on patient data. Patient data from medical records and digital health apps can be leveraged to build new tools that can help diagnose disease, remotely monitor and...
Through significant advancements in biomedical innovation, new promising gene and cell therapy treatments may be the key to unlocking the cure to debilitating genetic, oncologic, and other diseases that were once deemed incurable. The first...
The fuel for biomedical innovation is data. Data-driven patient participation — or patient contribution of their biospecimens, self-reported or wearable data, health record data, and other information — has emerged as a tool that may help...
If the objective of biomedical research is to spur innovation to create healthier communities, extend life, and more effectively treat or cure disease, then persistent inequities run counter to that goal and create unnecessary barriers to...
Clinical trial networks, as evidenced during the COVID-19 pandemic, really are “national critical infrastructure.” The pandemic revealed prominent gaps and stark differences in health outcomes across various populations. A community-based...
COVID-19 has focused the public’s attention on the racial and ethnic disparities in health outcomes, unequal access to health care, and some communities’ lack of trust and participation in medical research. These problems have been decades...
While the response to the COVID-19 pandemic has exposed many of the fault lines in the biomedical innovation ecosystem that have slowed progress for decades, we have also shown ourselves capable of innovating in ways we perhaps did not...
New blood-based technologies, known as multi-cancer early detection (MCED) tests, are entering the market and can identify multiple cancers early and simultaneously. These tests detect signals found in DNA that cancer cells shed into the...
FasterCures wants to ensure that the lessons of the COVID-19 crisis are not lost once the current urgency subsides — not only for combating future infectious diseases, but for conducting every other aspect of biomedical innovation...